1 / 16

Novel Restorative Therapy for Neurodegenerative Diseases Cognosci, Inc. at

Novel Restorative Therapy for Neurodegenerative Diseases Cognosci, Inc. at 2009 Life Sciences Venture Forum. Neurodegenerative Diseases: Unmet Medical Need. Alzheimer’s Disease Progressive loss of cognitive function 5 million patients in US, 20-30 million world wide

wylie-avery
Télécharger la présentation

Novel Restorative Therapy for Neurodegenerative Diseases Cognosci, Inc. at

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel Restorative Therapy for Neurodegenerative Diseases Cognosci, Inc. at 2009 Life Sciences Venture Forum

  2. Neurodegenerative Diseases:Unmet Medical Need • Alzheimer’s Disease • Progressive loss of cognitive function • 5 million patients in US, 20-30 million world wide • Economic impact: $4 B drug, $128 B total cost • No effective therapies to stop progression • Multiple Sclerosis • Progressive loss of motor function • 1 million patients worldwide • Economic impact: $5+ B drug • No restorative therapies

  3. Hippocampus: Memory and Learning Center Alzheimer’s Disease Brain Atrophy NORMAL ALZHEIMER’S

  4. COG1410 Reduces Pathology in AD Mice Tau Tangles Neuron Loss Amyloid Plaques Placebo COG1410

  5. COG Peptides Improve Learning and Memory 2-way ANOVA Interaction p = 0.036 Errors p <0.001 Trial Block p <0.001

  6. COG Peptides Improve Learning and Memory 2-way ANOVA Interaction p = 0.036 Errors p <0.001 Trial Block p <0.001

  7. COG Peptides Improve Learning and Memory 2-way ANOVA Interaction p = 0.036 Errors p <0.001 Trial Block p <0.001

  8. Inflammatory Myelin Destruction Recovery/ Remyelination Neurodegeneration/ Loss of Nerve Function Neuro-Restorative Therapy for MS

  9. Placebo 2 days culture Add Treatment Lysolecithin (16 hr) 4 days culture COG112 Cognosci Compounds Promote Remyelination Starting Slice Cerebellum Slice Culture

  10. COG112 Improves Clinical Motor Function Model of Primary Progressive Multiple Sclerosis COG112 Treated Placebo Treated Li et al. 2006

  11. Equals Anti-Inflammatory Activity + Neuro-Protective Activity + Re-Myelination Activity Neuro-Restorative Activity Cognosci Compounds are the First To Display Neuro-Restorative Activity

  12. Multiple Sclerosis Alzheimer’s Disease Traumatic Brain Injury Intracerebral Hemorrhage Rheumatoid Arthritis Leukemia Cognosci’s Pipeline Development Stage In vitro In vivo Preclin. COG112 COG1410/112 COG1410 IND Filing Q2’ 10 COG1410 COG133 COG445

  13. Intellectual Property DescriptionTypePhase Suppressing Method Issued US 7,205,280 Microglia Suppressing Composition Issued US 7,319,092 Microglia of Matter 2nd Generation Composition Examination COG Compounds of Matter US & PCT 3rd Generation Composition Submitted COG Compounds of Matter Novel Target Methods Submitted Patent counsel: Cooley Godward Kronish 13

  14. Mike Vitek, Ph.D. Founder, President, CSO 20 years experience with Roche, Lederle, Wellcome, GSK specializing in chronic degenerative diseases Dale Christensen, Ph.D. VP of Research & BD 15+ years experience in Drug Discovery and Development Fengqiao Li, Ph.D. Principal Research Scientist 10+ years experience in Research and Discovery Management Team & Scientific Advisors • Paul O’Connor, M.D. • Chair of Neurology, Univ. of Toronto • James Burke, M.D. • Duke University,Director of Clinical Research - Bryan Alzheimer's Disease Research Center • Bruce Trapp, Ph.D. • Cleveland Clinic, Chair of Neuroscience • Bill VanNostrand, Ph.D. • Stonybrook Univ. • Bruce Burnett, Ph.D. • Director, Regulatory Affairs • Duke Clinical Research Institute

  15. Milestones and Goals • Raised $15 M to date in SBIR funds • IND enabling safety/toxicology studies for 2 compounds ongoing now • Raise $8-10 M Series A Q4 ‘09 • File IND Application Q2 ‘10 • Complete Phase I Clinical Trials Q1 ‘11 • Partner with large pharma for Phase II and III clinical trials Q2 ‘11

  16. The First Restorative Therapies for Neurodegenerative Disease Dale J. Christensen, Ph.D. dchristensen@Cognosci.com Mobile: 919-801-2911

More Related